Eren Z et al. |
Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. |
2014 |
Kidney Blood Press. Res. |
pmid:25532067
|
Lee JW et al. |
Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-κB pathway in ischemia/reperfusion-induced acute kidney injury. |
2014 |
Biochem. Biophys. Res. Commun. |
pmid:24434153
|
Pauwels S et al. |
Minimal interference from paricalcitol (Zemplar®) in underivatized 1,25-dihydroxyvitamin D LC-MS/MS assays. |
2014 |
Clin. Chim. Acta |
pmid:24326126
|
Guo C et al. |
Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. |
2014 |
Mol Nutr Food Res |
pmid:24039193
|
Azak A et al. |
Effect of novel vitamin D receptor activator paricalcitol on renal ischaemia/reperfusion injury in rats. |
2013 |
Ann R Coll Surg Engl |
pmid:24112495
|
Chen B et al. |
Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects. |
2013 |
Bioorg. Med. Chem. Lett. |
pmid:24035340
|
Bae S et al. |
Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction. |
2013 |
J. Appl. Physiol. |
pmid:23429874
|
Duplancic D et al. |
The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. |
2013 |
Clin Interv Aging |
pmid:23430986
|
Piñera-Haces C et al. |
Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis. |
2013 |
Nefrologia |
pmid:23364629
|
Han T et al. |
Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. |
2013 |
Biomed Res Int |
pmid:23509710
|